Unlike many peptides that are primarily studied for growth hormone signaling or recovery pathways, DSIP is more commonly associated with sleep-related biological research
This depends on the outcomes of Phase 3 clinical trials, which are expected to be completed by the end of 2025
A notable pharmacokinetic paradox: despite a short half-life under 30 minutes, effects persist for weeks to months, attributed to gene pathway activation [PMID: 40789979]
For micro-dosing protocols using 0.05 to 0.075 mL per injection, look for syringes with half-unit markings if available
For solving scars, acne scars, reducing facial wrinkles, nourishing hair roots, stimulating hair growth
3.2 Annual comparison of PEDs samples (20202024) The numbers of the three types of samples provided for each year are summarized in Figure 2